News Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Nov 15, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it appointed Michael DiTolla, DDS, FAGD to its board of directors, effective November 14, 2019. The appointment...
- Nov 14, 2019Biorphen® Expected to Launch by End of November
DEER PARK, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Nov 13, 2019
DEER PARK, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Nov 08, 2019Eyes global delivery of Modular Immune Profile (MIP) Assay for Autoimmune Disease
LOS ANGELES, CA – November 8, 2019 – DxTerity Diagnostics Inc. has announced the signing of a multi-year licensing and supply agreement with Thermo Fisher Scientific. Under the terms of the...
- Nov 08, 2019Along with the release of new Longitudinal SLE Clinical Study Results, the diagnostics company announces the commercial launch of DxTerity Type 1 Interferon Testing
LOS ANGELES, CA – November 8, 2019 – DxTerity® Diagnostics Inc. has announced the results of a longitudinal clinical study with the Oklahoma Medical Research Foundation (OMRF) demonstrating...
- Nov 08, 2019—Despite Differing Study Designs, Patient Criteria and Geographies of the Two Landmark Clinical Trials, Results Were Consistent for AR101-Treated Patients Compared to Placebo—
HOUSTON--(BUSINESS WIRE)--Nov. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today...
- Nov 08, 2019
HOUSTON--(BUSINESS WIRE)--Nov. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed...
- Nov 08, 2019—New Data at ACAAI Reinforce the Need for Treatments to Reduce the Fear of Accidental Exposure to Peanut and Improve Emotional Well-Being for Adult Patients and Caregivers—
HOUSTON--(BUSINESS WIRE)--Nov. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today...
- Nov 08, 2019— Findings Suggest that a Strong Clinical History, in Combination with Evidence of Peanut Sensitization, is the Optimal Approach to Identify Highly Sensitive Peanut-Allergic Patients —
HOUSTON--(BUSINESS WIRE)--Nov. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today...
- Nov 07, 2019
FARMINGDALE, N.Y., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and...
- Nov 06, 2019
DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Nov 06, 2019--Webcast and conference call today at 4:30 p.m. ET--
BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 6, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Nov 06, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB :ASPCF) will announce its third quarter 2019 financial and operating results on Thursday, November 14, 2019 before the...
- Nov 06, 2019Third Quarter Net Revenue of $8.6 Million
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $8.6 million for the third quarter ended September 30, 2019. Third Quarter and Recent Operating and...
- Nov 04, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today...
- Nov 04, 2019
FARMINGDALE, N.Y., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and...
- Nov 01, 2019Current NATESTO® supply to the United States remains unaffected
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today provided an update on the temporary unavailability of NATESTO® in Canada and South Korea, following the...
- Oct 31, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Oct. 31, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Oct 31, 2019Recent Equity Raise and Line of Credit Provides Working Capital and Strengthened Balance Sheet to Fund Growth and Profitability
BIOLASE, Inc. (Nasdaq: BIOL), the global leader in dental lasers, today announced that it has secured a $3 million revolving line of credit from Pacific Mercantile Bank ("the Bank"), the wholly...
- Oct 30, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Oct. 30, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Oct 29, 2019
DxTerity Diagnostics has launched the IFN-1 Test for determining a systemic lupus erythematosus patient's type 1 interferon status and the risk of progressing to lupus nephritis. The firm launched...
- Oct 28, 2019
FARMINGDALE, N.Y., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Oct 24, 2019
BIOLASE, Inc. (Nasdaq: BIOL), the global leader in dental lasers, today announced the pricing of an underwritten public offering of 7,820,000 shares of its common stock at a price to the public of...
- Oct 23, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced it will host a Key Opinion Leader (KOL) meeting on new, unique clinical evidence supporting the...
- Oct 23, 2019More Than 250 Dental Professionals Attended The Event To Learn The Latest Trends And Innovations In Dentistry From Leading Industry Experts
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, hosted the inaugural Advancing Dentistry Symposium in San Diego, California Oct. 18-19. More than 250 professionals in the dental...